Lexicon Pharmaceuticals (LXRX) Misses Q1 View By 3c
LXRX Hot Sheet
EPS Growth %: +23.1%Financial Fact:
Consolidated net loss: -29.87M
Today's EPS Names:
TARO, BRLI, TLB, More
Lexicon Pharmaceuticals (Nasdaq: LXRX) reports Q1 LOSS of $0.16, 3 cents below the analyst estimate of ($0.13). Revenue for the quarter was $4.2 million, versus the consensus of $5.96 million.
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team.
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- UPDATE: NetApp, Inc. (NTAP) Tops Q4 EPS by 3c; Guides Q1 Lower
- AFC Enterprises, Inc. (AFCE) Tops Q1 EPS by 4c; Raises FY12 Comps Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
